Sector
PharmaceuticalsOpen
₹684.95Prev. Close
₹680.05Turnover(Lac.)
₹18.2Day's High
₹700Day's Low
₹680.0552 Week's High
₹74852 Week's Low
₹244.5Book Value
₹497.17Face Value
₹10Mkt Cap (₹ Cr.)
246.7P/E
15.25EPS
44.58Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 3.57 | 3.57 | 3.57 | 3.57 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 151.23 | 152.48 | 133.07 | 112.1 |
Net Worth | 154.8 | 156.05 | 136.64 | 115.67 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 96.56 | 70.57 | 92.47 | 95.47 |
yoy growth (%) | 36.82 | -23.67 | -3.13 | 23.96 |
Raw materials | -50.06 | -40.02 | -53.57 | -48.67 |
As % of sales | 51.84 | 56.71 | 57.93 | 50.98 |
Employee costs | -10.18 | -9.7 | -8.56 | -6.75 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 17.59 | 9.11 | 18.04 | 24.88 |
Depreciation | -1.98 | -2 | -1.56 | -1.55 |
Tax paid | -4.05 | -1.98 | -5.6 | -8.26 |
Working capital | 11.57 | 22.79 | -3.33 | 10.21 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.82 | -23.67 | -3.13 | 23.96 |
Op profit growth | 199.58 | -65.14 | -34.33 | 41.59 |
EBIT growth | 92.21 | -49.25 | -27.44 | 42.53 |
Net profit growth | 90.09 | -42.7 | -23.62 | 31.45 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Sheela R Kamdar
Whole-time Director
Girish Dhameja
Director & CFO
Sushma Shashi Kadkade
Independent Director
Saurabh Shah
Independent Director
Malay Doshi
Non Executive Director
Rajendrasinh Rana
Company Sec. & Compli. Officer
Dhwani Desai
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Coral Laboratories Ltd
Summary
Coral Laboratories Limited (CLL) was established in February, 1997. Carol Labs are into manufacturing of Generic Branded, Nutraceuticals, OTC and Herbal Medicines. The Company produces various pharmaceutical formulations in 3 different locations all over India. It has plants at Daman and Dehradun . The Company was promoted by Navin B Doshi of the DWD group. To manufacture pharmaceutical formulations like tablets, capsules, liquid and topical preparation, the Company went into public issue in March 94 at a total cost of Rs.2.5 crores. It setup an additional ultra-modern manufacturing unit at Daman and the said Unit started the commercial production during March 2004. It started the commercial production at Dehradun Plant in September, 2006.
Read More
The Coral Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹691.05 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Coral Laboratories Ltd is ₹246.70 Cr. as of 22 Jul ‘24
The PE and PB ratios of Coral Laboratories Ltd is 15.25 and 1.37 as of 22 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Coral Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Coral Laboratories Ltd is ₹244.5 and ₹748 as of 22 Jul ‘24
Coral Laboratories Ltd's CAGR for 5 Years at 28.71%, 3 Years at 17.32%, 1 Year at 168.21%, 6 Month at 51.36%, 3 Month at 83.10% and 1 Month at 5.98%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.